$MEIP
MEI Pharma, Inc.

2021 Q2 Form 10-Q Financial Statement

#000119312521153237 Filed on May 06, 2021

View on sec.gov

Income Statement

Concept 2021 Q2 2021 Q1 2020 Q1
Revenue $19.38M $8.109M $1.244M
YoY Change -24.02% 551.85% -0.4%
Cost Of Revenue $0.00 $405.0K $860.0K
YoY Change -100.0% -52.91% -26.05%
Gross Profit $19.38M $7.704M $384.0K
YoY Change -22.55% 1906.25% 346.51%
Gross Profit Margin 100.0% 95.01% 30.87%
Selling, General & Admin $6.634M $6.220M $3.860M
YoY Change 46.45% 61.14% 6.34%
% of Gross Profit 34.24% 80.74% 1005.21%
Research & Development $16.29M $17.88M $8.963M
YoY Change 107.3% 99.53% -1.19%
% of Gross Profit 84.09% 232.14% 2334.11%
Depreciation & Amortization $65.00K $80.00K $30.00K
YoY Change 225.0% 166.67% 50.0%
% of Gross Profit 0.34% 1.04% 7.81%
Operating Expenses $22.93M $17.88M $8.963M
YoY Change 85.05% 99.53% -1.19%
Operating Profit -$3.551M -$16.40M -$12.44M
YoY Change -128.12% 31.76% -1.37%
Interest Expense $7.100M -$9.210M $8.110M
YoY Change -122.82% -213.56% -271.1%
% of Operating Profit
Other Income/Expense, Net $4.000K -$13.00K $0.00
YoY Change -100.0%
Pretax Income $3.553M -$31.31M -$4.330M
YoY Change -119.23% 623.09% -75.06%
Income Tax $8.000K
% Of Pretax Income 0.23%
Net Earnings $3.545M -$25.62M -$4.329M
YoY Change -119.19% 491.87% -75.05%
Net Earnings / Revenue 18.29% -315.97% -347.99%
Basic Earnings Per Share -$0.23 -$0.04
Diluted Earnings Per Share $31.49K -$0.23 -$0.04
COMMON SHARES
Basic Shares Outstanding 112.6M 112.6M 106.0M
Diluted Shares Outstanding 112.6M 106.0M

Balance Sheet

Concept 2021 Q2 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $153.4M $164.6M $92.80M
YoY Change -15.98% 77.37% 12.76%
Cash & Equivalents $8.543M $9.745M $7.438M
Short-Term Investments $144.9M $154.9M $85.40M
Other Short-Term Assets $3.809M $4.500M $2.100M
YoY Change -23.82% 114.29% -34.38%
Inventory
Prepaid Expenses
Receivables $7.400M $500.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $164.8M $176.6M $95.40M
YoY Change -21.01% 85.07% 11.66%
LONG-TERM ASSETS
Property, Plant & Equipment $1.507M $1.569M $986.0K
YoY Change 39.02% 59.13% 362.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $9.281M $9.561M $1.221M
YoY Change 756.18% 683.05% 152.8%
TOTAL ASSETS
Total Short-Term Assets $164.8M $176.6M $95.40M
Total Long-Term Assets $9.281M $9.561M $1.221M
Total Assets $174.1M $186.1M $96.62M
YoY Change -16.99% 92.63% 12.45%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.355M $5.571M $2.492M
YoY Change 160.77% 123.56% 26.56%
Accrued Expenses $8.402M $7.762M $5.287M
YoY Change 37.96% 46.81% -7.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.21M $33.38M $10.26M
YoY Change -13.27% 225.4% -13.45%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $104.4M $107.8M $11.90M
YoY Change -3.49% 805.88% -67.13%
Total Long-Term Liabilities $104.4M $107.8M $11.90M
YoY Change -3.49% 805.88% -67.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.21M $33.38M $10.26M
Total Long-Term Liabilities $104.4M $107.8M $11.90M
Total Liabilities $124.6M $141.2M $22.13M
YoY Change -5.23% 538.01% -53.95%
SHAREHOLDERS EQUITY
Retained Earnings -$319.7M -$322.1M -$258.8M
YoY Change 15.32% 24.48% 10.45%
Common Stock $369.2M $367.1M $333.3M
YoY Change 3.86% 10.14% 22.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $49.47M $55.73M $74.50M
YoY Change
Total Liabilities & Shareholders Equity $174.1M $186.1M $96.62M
YoY Change -16.99% 92.63% 12.45%

Cashflow Statement

Concept 2021 Q2 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $3.545M -$25.62M -$4.329M
YoY Change -119.19% 491.87% -75.05%
Depreciation, Depletion And Amortization $65.00K $80.00K $30.00K
YoY Change 225.0% 166.67% 50.0%
Cash From Operating Activities -$11.25M -$15.65M -$10.29M
YoY Change -116.28% 52.09% -9.26%
INVESTING ACTIVITIES
Capital Expenditures -$8.000K $0.00 -$780.0K
YoY Change -92.0% -100.0% 1850.0%
Acquisitions
YoY Change
Other Investing Activities $9.996M $15.39M $9.880M
YoY Change -111.77% 55.77% 0.82%
Cash From Investing Activities $9.988M $15.39M $9.100M
YoY Change -111.75% 69.12% -6.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 68.00K 120.0K -10.00K
YoY Change -99.67% -1300.0% -104.0%
NET CHANGE
Cash From Operating Activities -11.25M -15.65M -10.29M
Cash From Investing Activities 9.988M 15.39M 9.100M
Cash From Financing Activities 68.00K 120.0K -10.00K
Net Change In Cash -1.198M -140.0K -1.200M
YoY Change -124.45% -88.33% -9.77%
FREE CASH FLOW
Cash From Operating Activities -$11.25M -$15.65M -$10.29M
Capital Expenditures -$8.000K $0.00 -$780.0K
Free Cash Flow -$11.25M -$15.65M -$9.510M
YoY Change -116.25% 64.56% -15.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
29442000
CY2021Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
112592000
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
111514000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6215000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3864000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17780000
CY2020Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
40483000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12189000
CY2021Q1 us-gaap Liabilities
Liabilities
141160000
CY2021Q1 us-gaap Costs And Expenses
CostsAndExpenses
24504000
CY2020Q1 us-gaap Costs And Expenses
CostsAndExpenses
13687000
us-gaap Costs And Expenses
CostsAndExpenses
72292000
CY2020Q2 us-gaap Liabilities
Liabilities
131510000
us-gaap Costs And Expenses
CostsAndExpenses
40584000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-31313000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4329000
CY2021Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
186122000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-65166000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
209728000
CY2021Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-27540000
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q1 us-gaap Revenues
Revenues
2418000
CY2020Q1 us-gaap Revenues
Revenues
1244000
CY2021Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q1 us-gaap Common Stock Value
CommonStockValue
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
us-gaap Revenues
Revenues
15419000
CY2021Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
367055000
us-gaap Revenues
Revenues
3409000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
355452000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22086000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-12443000
CY2021Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-322093000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277234000
us-gaap Operating Income Loss
OperatingIncomeLoss
-56873000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37175000
CY2021Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-9272000
CY2020Q1 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
7732000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
44962000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
11035000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
8562000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
78218000
CY2021Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
58000
CY2021Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
405000
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
860000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1408000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2189000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17884000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8963000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
53104000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26206000
CY2021Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000
CY2021Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2020Q1 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
382000
CY2021Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
226000000
CY2021Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
112592000
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
111514000
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2021Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1569000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1084000
CY2021Q1 us-gaap Assets
Assets
186122000
CY2020Q2 us-gaap Assets
Assets
209728000
CY2021Q1 us-gaap Short Term Investments
ShortTermInvestments
154879000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
170299000
CY2021Q1 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
164624000
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
182630000
CY2021Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11937000
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5594000
CY2021Q1 us-gaap Assets Current
AssetsCurrent
176561000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
208644000
CY2021Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
5571000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2437000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7762000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6090000
CY2021Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
19143000
CY2020Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14777000
CY2021Q1 us-gaap Liabilities Current
LiabilitiesCurrent
33376000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
23304000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
497000
us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
1074000
us-gaap Net Income Loss
NetIncomeLoss
-44859000
us-gaap Net Income Loss
NetIncomeLoss
-27540000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.28
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.40
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.28
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112557000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105999000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
112505000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85995000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
112557000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
105999000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113991000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85995000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
11035000
us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
8562000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
215000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
90000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
6343000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
169000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
3134000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2295000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1672000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
667000
us-gaap Profit Loss
ProfitLoss
-44859000
us-gaap Profit Loss
ProfitLoss
-27540000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
7377000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2479000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
700000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
785000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
325162000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
90324000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
340582000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
69863000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
14720000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-21246000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
265000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
72000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3401000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53948000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20707000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34854000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2586000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2152000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12331000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9590000
CY2021Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9745000
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7438000
CY2020Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
2605000
CY2019Q2 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
CY2021Q1 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
0
CY2020Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
335000
CY2019Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
511000
CY2021Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
7432000
CY2020Q1 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
353000
CY2020Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
82497000
CY2019Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
7771000
CY2021Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
89877000
CY2020Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
5292000
CY2021Q1 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
89900000
meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00
meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-27540000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-44859000
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4329000
CY2021Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-31313000
CY2021Q1 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
74500000
CY2021Q1 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
100000
CY2021Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
10200000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2021Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2020Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0
CY2020Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020Q1 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
74000
meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4
CY2021Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
70734000
CY2020Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
67723000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2645000
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1550000
us-gaap Share Based Compensation
ShareBasedCompensation
8196000
us-gaap Share Based Compensation
ShareBasedCompensation
5434000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11252976
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
5763300
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.40
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
119042
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
223828
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.65
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
16673406
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.01
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7802361
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.74
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.32
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.60
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9775096
CY2021Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
7006856
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.005
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.018
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.811
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.736
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: times new roman; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="text-indent: 4%; font-family: times new roman; font-size: 10pt; margin-top: 6pt; margin-bottom: 0pt;"><div style="font-family: &quot;times new roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates. </div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2645000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
47930000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2994000
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
159000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
72000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2113000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
47280000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-20217000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2019Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
48451000
CY2019Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1771000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
77285000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4329000
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-8000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-2092000
CY2020Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3136000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
124000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2942000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
82328000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-11454000
CY2020Q4 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
15000
CY2020Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2609000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
73498000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-31313000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
126000
CY2021Q1 meip Stockissuedduringperiodvaluestockwarrantsexercised
Stockissuedduringperiodvaluestockwarrantsexercised
6000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1550000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
2300000
meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
15000000
CY2020Q1 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
800000
CY2021Q1 meip Revenue Performance Obligation Amount
RevenuePerformanceObligationAmount
2300000
CY2020Q2 meip Receivable For Foreign Tax Withholding
ReceivableForForeignTaxWithholding
20420000
CY2021Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7992000
CY2021Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
900000
CY2021Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7608000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
482000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
74498000
meip Non Cash Lease Expense
NonCashLeaseExpense
697000
meip Increase Or Decrease In Receivable For Foreign Tax Withholding
IncreaseOrDecreaseInReceivableForForeignTaxWithholding
20420000
meip Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
-181000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8689000
meip Proceeds From Previously Issued Common Stock
ProceedsFromPreviouslyIssuedCommonStock
5274000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
48602000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3136000
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Entity Small Business
EntitySmallBusiness
true
dei Security12b Title
Security12bTitle
Common Stock
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
368000
CY2021Q1 meip Aggregate Value Of Securities Available Under Agreement
AggregateValueOfSecuritiesAvailableUnderAgreement
175700000
meip Unsold Securities Shares And Warrants Under Agreement
UnsoldSecuritiesSharesAndWarrantsUnderAgreement
107500000
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-1000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-8000
CY2021Q1 meip Cash And Cash Equivalentsshort Term Investments And Common Stock Proceeds Receivable
CashAndCashEquivalentsshortTermInvestmentsAndCommonStockProceedsReceivable
164600000
meip Dilutive Securities Effect On Basic Earnings Per Share Change In Fair Value Of Warrant Liability
DilutiveSecuritiesEffectOnBasicEarningsPerShareChangeInFairValueOfWarrantLiability
-20307000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27036000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
21402000
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27126000
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32651000
CY2021Q1 meip Initial Recognition Of Operating Lease Right Of Use Asset
InitialRecognitionOfOperatingLeaseRightOfUseAsset
8700000
us-gaap Operating Lease Cost
OperatingLeaseCost
603000
us-gaap Operating Lease Cost
OperatingLeaseCost
1130000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
201000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
377000
us-gaap Operating Lease Payments
OperatingLeasePayments
603000
us-gaap Operating Lease Payments
OperatingLeasePayments
615000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
201000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
369000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1710000
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0750
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8508000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
2556000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
11064000
CY2021Q1 meip Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
3122000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1168000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1612000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1565000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1519000
dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
MEIP
dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001262104
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
112591778
meip Number Of Warrants Exercised
NumberOfWarrantsExercised
2617
meip Number Of Shares Issued On Warrant Exercise
NumberOfSharesIssuedOnWarrantExercise
964
CY2021Q1 meip Profits And Costs Sharing Ratio
ProfitsAndCostsSharingRatio
0.5
meip Receivables Amounts Billed
ReceivablesAmountsBilled
15744000
meip Receivables Amounts Billed
ReceivablesAmountsBilled
1088000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-18349000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
930000
meip Receivables Payments Received
ReceivablesPaymentsReceived
-1014000
meip Contract Assets Billable Amounts
ContractAssetsBillableAmounts
22841000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-15744000
meip Contract Assets Amounts Billed
ContractAssetsAmountsBilled
-1088000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2100000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
meip Warrants Issued Pursuant To Cashless Exercise
WarrantsIssuedPursuantToCashlessExercise
6000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1486000
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA

Files In Submission

Name View Source Status
0001193125-21-153237-index-headers.html Edgar Link pending
0001193125-21-153237-index.html Edgar Link pending
0001193125-21-153237.txt Edgar Link pending
0001193125-21-153237-xbrl.zip Edgar Link pending
d138219d10q.htm Edgar Link pending
d138219dex311.htm Edgar Link pending
d138219dex312.htm Edgar Link pending
d138219dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g138219g0504025156354.jpg Edgar Link pending
g138219g0504025156572.jpg Edgar Link pending
g138219g0504025156728.jpg Edgar Link pending
meip-20210331.xml Edgar Link completed
meip-20210331.xsd Edgar Link pending
meip-20210331_cal.xml Edgar Link unprocessable
meip-20210331_def.xml Edgar Link unprocessable
meip-20210331_lab.xml Edgar Link unprocessable
meip-20210331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending